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 Background: Inflammatory arthritis in childhood is variable both in terms of presentation and 
outcome. This analysis describes disease activity during the first year following presentation to a 
paediatric rheumatologist and identifies predictors of moderate to severe disability (defined using a 
Childhood Health Assessment Questionnaire (CHAQ) score ≥0.75) at one-year.  
Methods: CAPS recruits children <16 years with new inflammatory arthritis persisting for ≥ 2 weeks 
from five UK tertiary referral centres. Demographics, disease features, joint count, Childhood Health 
Assessment Questionnaire (CHAQ), physician’s global assessment (PGA), parent’s general 
evaluation of well-being (PGE), ESR and treatment, are collected at first presentation, 6 months, then 
yearly. Independent predictors of CHAQ≥0.75 at one-year in children with JIA were identified using 
multivariable logistic regression models. 
Results: 740 children were included; median age at presentation 7.6 years, 64% girls. During the 
first year, 85% received NSAIDs, 70% intra-articular corticosteroids, 47% methotrexate, and 27% 
systemic steroids (oral or IV). Median presenting CHAQ score was 0.63 and decreased to 0.25 at 1 
year; 32% had CHAQ≥0.75 at 1 year. The strongest predictor of CHAQ≥0.75 at one year was 
CHAQ≥0.75 at presentation (OR 3.92 (95% CI 2.17, 7.09)). Additional predictors included female 
gender and higher PGE   
Conclusion: Although CHAQ score improved in most children, the strongest predictor of persistent 
disability at one-year was moderate to severe disability at first presentation. Follow-up beyond one-
year will assess whether CHAQ at presentation will continue to be a predictor of future poor 
outcome. 
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Inflammatory arthritis is a chronic debilitating disease of childhood. It has been estimated that each 
year, approximately 10 per 100,000 children will develop an inflammatory arthritis (1), with many 
subsequently being diagnosed with juvenile idiopathic arthritis (JIA). Although the disease course 
can be variable, with periods of activity followed by remission, previous studies have shown that up 
to 70% of children continue to report disability and limitation of their activities into adulthood (2-7).  
However, comparing across studies has been difficult for many reasons, including variability in the 
classification of childhood arthritis (8-12), differences in study design, and changes in treatments 
over time. In addition, most of these previous studies have based estimates of the chronicity and 
severity of this disease on retrospective medical record reviews, which may bias towards a more 
severe group of patients. As a result, many studies lack specific measures of disease activity at first 
presentation, making it difficult to predict later outcomes based on early presentation.  
Finally, the change in the treatment of JIA towards earlier aggressive therapy is likely to have 
changed outcomes for many groups of patients, thus making previous estimates of outcomes less 
applicable to children today. Therefore, data concerning the early disease course in children 
presenting with inflammatory arthritis in this modern treatment era remains limited and there is a 
need to study prospective inception cohorts of children with inflammatory arthritis such that all 
aspects of the disease course can be captured, from the very mild to the most severe.  Identifying 
early those children most likely to have a severe disease course may help to target therapies to those 
most likely to have poor outcomes and avoid over-treatment in those most likely to experience 
spontaneous remission. 
The Childhood Arthritis Prospective Study (CAPS) is an ongoing prospective longitudinal inception 
cohort study which aims to provide information on the long-term outcome of children with 
inflammatory arthritis following routine care in the UK. The aim of the current analysis was to 
describe the outcomes of children with JIA one-year following first presentation to paediatric 
rheumatology and to identify factors which predicted moderate to severe disability at one year. 
Methods 
Study population: 
The CAPS study began recruitment in 2001. Details of this study have been described elsewhere(13). 
In brief, children aged < 16 years presenting to one of 5 paediatric rheumatology referral centres 
(Liverpool, Manchester, Glasgow, Newcastle-upon-Tyne, and London) with a new diagnosis of 
inflammatory arthritis (in at least one joint) present for at least 2 weeks are approached to participate. 
 4 
Exclusion criteria are septic arthritis, haemarthrosis, arthritis caused by malignancy or trauma, 
connective tissue disorders such as systemic lupus erythematosus (SLE), mixed connective tissue 
disease or dermatomyositis. Currently, the study continues to recruit new children. The study was 
approved by the UK Northwest Multicentre Research Ethics Committee. Parent(s)/guardians are 
asked to provide written consent and children, if considered able, are asked to provide assent. 
Baseline Data Collection 
At the first visit, the rheumatologist performs a rheumatological exam and completes a 100 mm 
Physician Global Assessment (PGA). They are asked to assign an ILAR subtype if the suspected 
diagnosis is JIA. The parent(s) and child are interviewed by a rheumatology research nurse and the 
medical records are reviewed to extract information on demographics, diagnosis, disease 
characteristics including disease duration at first presentation, past medical history, medications and 
relevant blood tests. Blood tests are only done as part of routine care and results are recorded when 
performed. The parent (or where appropriate the child) complete a Childhood Health Assessment 
Questionnaire (CHAQ) validated for use in the UK population (14), a 100 mm pain VAS and a 100 
mm parent general evaluation (PGE).  
Follow-up Data: 
Follow-up study visits are arranged at 6 months following first presentation and then yearly for a 
minimum of 5 years. At each follow-up the child again undergoes a rheumatological examination, and 
the PGA, PGE, CHAQ, and a pain VAS are completed. Again, details of medications taken since last 
follow-up are extracted from the medical record, as are results of any relevant blood tests. Children 
who are discharged from rheumatology care continue to be followed by the rheumatology research 
nurse for at least 2 additional years. 
Analysis:  
This analysis was limited to children with a diagnosis of JIA (that is, arthritis persisting for 6 weeks or 
more in one or more joint, of no other attributable cause) who had completed at least one year of 
follow-up. Demographic and disease characteristics including the JIA Core Outcome Variables (active 
and limited joint count, PGA, PGE, CHAQ score, ESR)(15) and pain measured at first presentation and 
at one-year are presented for the entire cohort and by ILAR subtype. The ILAR subtype for this 
analysis was assigned at 6 months of symptom duration. If children had been symptomatic for more 
than 6 months at first paediatric rheumatology visit, the ILAR subtype was assigned at the first 
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presentation. If the child had been symptomatic for less than 6 months, the subtype was assigned at the 
6 month follow-up visit. The values of each disease characteristic at baseline and at one one-year were 
compared within the whole cohort and within each individual subtype using Wilcoxon matched-pairs 
test. 
A CHAQ score ≥0.75 was selected to indicate moderate to severe levels of disability. Previous 
studies which have attempted to correlate CHAQ scores with parent or child reports of the level of 
disability have found a value of 0.75 to be a good discriminate between none to mild and moderate to 
severe disability (16;17). Multivariable logistic regression models were developed to identify (1) 
factors associated with this high CHAQ at baseline and (2) predictors (measured at first presentation) 
of a high CHAQ at one-year. Co-variates in the models included age at first presentation, gender, 
study site, symptom duration at first presentation (defined using month of first reported symptom 
onset), active and limited joint count, ESR (per 10mm/hr increments), PGA (per 10mm increments), 
PGE (per 10mm increments) and pain score (per 10mm increments). Missing data were imputed 
using multiple imputation (number of repeated imputations = 35) (18;19). The following variables 
were included in the imputation: age, gender, symptom duration, active joint count, ESR, PGA, PGE, 
CHAQ and pain scores. Regression models were run with both unimputed and imputed data and the 
results of both are presented. The results are presented as odds ratios (OR) with 95% confidence 
intervals (CI). All analyses were performed in Stata version 9.2 (Statacorp 2003, College Station, 
USA). 
 
Results 
To March 2009, CAPS had registered 917 with JIA. Of these, 740 had reached one-year of follow-
up. The study participants were primarily Caucasian (93%) with a median age at first presentation of 
7.6years (Interquartile range (IQR) 3.6, 11.5); 64% were female (Table 1). The median symptom 
duration at first presentation was 5.2 months (IQR 2.5, 10.4). The most common ILAR subtype was 
oligoarthritis (48%). At first presentation, the median active joint count was 2 (IQR 1, 5). The 
median ESR was 20 mm/hr (IQR 6, 46), median pain score was 32 (IQR 9, 57) and the median 
CHAQ was 0.63 (IQR 0.13, 1.38)) (Tables 2 and 3). For 91 children (19%), the presenting CHAQ 
score was zero.  
After one-year of follow-up, all subtypes of JIA had experienced improvements in scores (Tables 2 
and 3). The median active and limited joint count at one-year was 0 (IQR 0, 1). The median ESR had 
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fallen to 9 (IQR 4, 20) and the median pain score had decreased to 9 (IQR 1, 32). CHAQ scores had 
also improved with a median CHAQ score of 0.25 (IQR 0.00, 1.00) at one year. 26% had a CHAQ 
score of 0 at one year. The one exception was a deterioration in the PGE in children with RF(+) 
polyarthritis, although this did not reach statistical significance. Of those presenting with 
oligoarthritis in the first 6 months (n=353), 16 (5%) children had evolved to the extended subtype at 
one-year. Although small numbers prevent robust estimates, there were no significant differences in 
age, gender, active or limited joint counts or ESR at first presentation between those children with 
persistent oligoarthritis and those who extended. 
 
Over the course of the first year following presentation, 85% of children received treatment with 
NSAIDs (Table 4), 70% of children had received an intra-articular steroid injection, with a median of 
1 injected joints/child (range 1-35) and 47% had started on methotrexate (MTX). Approximately half 
of the children had received their first dose of MTX within 6 months of disease onset (n=169 (48%)). 
Eighty-seven percent of children had received their first dose of MTX within 6 months of first 
presentation to a paediatric rheumatologist and 57% within the first month. Seven percent of children 
had already received biologic therapy before the end of the first year. 
CHAQ score ≥0.75 at first presentation was significantly associated with active joint count, ESR, 
PGE and pain scores (Table 5).  At one-year, the proportion of children with a CHAQ score ≥0.75 
had fallen from 50% to 32%. The highest scores were again seen in children with systemic arthritis, 
polyarthritis (RF(+) and RF(-)) and extended oligoarthritis.  The majority of children with a CHAQ 
score <0.75 at first presentation continued to have a CHAQ<0.75 at one-year although 14% of 
children with an initial low CHAQ had a one-year CHAQ ≥0.75. The strongest predictor of a CHAQ 
score ≥0.75 at one-year was a CHAQ score ≥0.75 at first presentation (OR 3.92 (95% CI 2.17, 
7.09)). In addition, higher CHAQ scores at one year were less common in boys (OR 0.62 (95% CI 
0.37, 1.03)) and more common in those with higher parent general evaluation at baseline (OR 1.16 
per 10mm VAS (95% CI 1.01, 1.32)). Other factors, including symptom duration at first 
presentation, ESR, pain scores, and PGA were not independently associated with CHAQ ≥0.75 at 
one-year.  
Discussion 
This study represents the largest prospective report of early outcomes in a modern inception cohort 
of children presenting to paediatric rheumatology with inflammatory arthritis. In addition, the results 
are not limited to a single centre or rheumatologist, but represent the current outcomes at 5 of the 
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largest paediatric rheumatology centres in the UK who practice within the guidelines as set out by 
the British Society for Paediatric and Adolescent Rheumatology (BSPAR) consensus document on 
the Standards Of Care For Children And Young People With Juvenile Idiopathic Arthritis (see 
http://www.bspar.org.uk/downloads/clinical_guidelines/ Standards_of_Care.pdf).  
 
Over 50% of children presented with oligoarthritis and a significant proportion of children were 
found to have no active or limited joints at the one-year assessment. However, even in this era of 
modern therapies, there still remained a subgroup of children with persistently active disease. Not 
surprisingly, the strongest predictor of disability at one-year was the level of disability at the first 
presentation, which likely encompasses many other features of the disease, including active joint 
counts and pain. High levels of disability at first presentation have also been shown to be a strong 
predictor of future disability in studies of adults with rheumatoid arthritis (RA)(20). 
In our study, we found an association between higher level of disability among girls at one-year, 
which is consistent with earlier reports (21;22). Oen specifically looked at predictors of CHAQ score 
≥0.75 after a mean of 12 years of disease in her retrospective cohort of children with JRA. Although 
specific details of disease activity at disease presentation were not available, there was also a trend 
towards less disability, albeit at a much later time point in disease, in males (23). The reasons why 
females should do worse than males is not clear. However, an over-representation of females in 
certain subgroups, particularly RF(+) polyarthritis, which often has a more severe course, may  
explain part of the association.  
Few previous studies have specifically looked at the early course of disease in children with 
inflammatory arthritis and fewer still have specifically classified children according to the ILAR JIA 
subtypes, making direct comparisons of our results difficult. A retrospective study by Bowyer et al 
described outcomes at one and five years in children with JRA presenting between 1992 and 1997 
(24) and found that the vast majority had milder levels of disability at the end of the first year 
(defined as Steinbrocker class I or II). However, children with spondyloarthropathies and/or psoriasis 
were specifically excluded. In our study, 24% of children with ERA and 30% of children with PSA 
had significant disability (CHAQ ≥ 0.75) at one-year.  
The results of our study are similar to those found in a single centre inception cohort of 197 children 
with JRA or Juvenile Spondyloarthropathy (JSpA) in Norway (25) which also found that CHAQ 
score in the first 6-months of disease was the strongest predictor of disability, measured using 
CHAQ, at 3-years. Similarly, they also found that the parent’s global assessment of child’s well-
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being was a predictor of CHAQ at 3 years, suggesting there are other important aspects of the child’s 
arthritis observed by the parent but independent of the physician, which are important in determining 
functional outcome. 
It is difficult to know at this time point specifically what role DMARDs and other anti-rheumatic 
therapies played in the improvement of CHAQ scores in these children and how much was the 
natural variability within the disease. An Italian study of 227 children with JIA found that patterns of 
disability fluctuated between states of mild, moderate and severe disability in 40% of children 
measured over a median of 3 years (26). One quarter of children demonstrated a continuous 
improvement in disability over this same period and a further quarter demonstrated persistently 
stable low disability levels. Further analyses of the CAPS cohort will also confirm whether or not 
early treatment with DMARDs significantly improves longer-term outcome. In this study the biggest 
determinant in determining how long after disease onset MTX was started was the time taken to first 
paediatric rheumatology assessment, as the majority of children who did start MTX did so soon after 
this first appointment. However, at this early stage, delay to first presentation was not found to be a 
predictor of high CHAQ at one year. Continued follow-up will determine if this continues to be true. 
A possible limitation to our study may have been the impact of missing data. In our study, the 2 
variables with the most missing data at baseline included the ESR (23% missing) and the CHAQ 
score (30% missing). As per ethical approval, blood tests could only be taken as part of routine 
clinical practice and therefore, if an ESR had not been performed, this value would not be available. 
Although most centres now collect CHAQ as part of routine clinical care, this was not always the 
case over the study period. In addition, for some families, due to circumstances at the time of first 
presentation, parents may have been unable to complete these forms at the first visit. However, 
despite this missing data, all children had available information for multiple imputation. To confirm 
the validity of our multiple imputation, we also ran regression models in those with complete data 
only. This analysis also confirmed the significant association with CHAQ ≥0.75 at baseline and 
calculated similar point estimates for PGE and gender, albeit with wider confidence intervals, likely 
due to the smaller sample size. 
 We specifically chose not to include the JIA subtype as a predictor of disability at one year in our 
multivariable model. Although it was clear from looking at crude results that certain subtypes had a 
more severe course over the first year there is likely to be much variability within each subgroup. 
The common factor that linked all of these subgroups to outcome was disease severity at first 
presentation. As many children may present with persistent inflammatory arthritis and not fit into a 
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specific ILAR category, instead either being classified as “Undifferentiated”, we felt it important to 
include other easily measurable factors, such as joint counts, pain score, disability and ESR that are 
common to all children presenting with inflammatory arthritis. With time, it may be more sensible to 
include these subtypes into further predictive models. In addition, there may be certain characteristics 
within each subtype which may predict a worse disease course. For example, 33 of the 51 children 
with ERA had HLA-B27 testing results of whom 64% were positive.  
CONCLUSIONS: 
This analysis has shown that even within a short one-year period following presentation with 
inflammatory arthritis, the majority of children will have a significant improvement in pain, joint 
inflammation and disability, with many children having no active or limited joints. However, after 1 
year, one-third of children continued to have moderate to severe levels of disability, despite 
treatment with intra-articular steroid injections or DMARDs. These higher levels of disability were 
predicted by higher levels of CHAQ at baseline, higher parent general evaluations and female 
gender. Further follow-up of this cohort will continue to explore the longer term outcomes in these 
children and confirm if these same predictors (measured at first presentation) or other factors, such as 
any delay to treatment, will predict outcome of disability at later stages of the disease.  
Word Count: 2822 
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Table 1 Demographic Characteristics at Time of Study Entry 
 
ILAR n (% of total) Age at Symptom Onset (years) 
median (IQR) 
Age at First Presentation (years) 
median (IQR) 
Female 
 n (% within each subtype)
     
Whole Cohort 740 (100) 6.6 (2.8, 10.7) 7.6 (3.6, 11.5) 476(64) 
Systemic Arthritis 42 (6) 6.4 (3.4, 10) 6.7 (3.6, 10.1) 32 (76) 
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Persistent Oligoarthritis 353 (48) 5.5 (2.4, 9.8) 6.5 (3.1, 10.8) 225 (64) 
Extended Oligoarthritis 32 (4) 4.3 (1.9, 8.4) 5.3 (2.7, 9.4) 23 (72) 
RF (-) Polyarthritis 148 (20) 5.8 (2.2, 9.4) 7.5 (3.3, 10.6) 110 (74) 
RF (+) Polyarthritis 23 (3) 11.4 (9.1, 13.4) 12.2 (9.9, 14.8) 21 (91) 
ERA 51 (7) 11.8 (10.1, 13.1) 13 (11.3, 13.9) 6 (12) 
PSA 61 (8) 9.8 (4.3, 11.6) 11 (5.7, 13) 40 (66) 
Undifferentiated 30 (4) 7.1 (2.7, 9.8) 8.9 (5.8, 10.9) 19 (63) 
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Table 2 Disease Activity at Baseline and One-Year (Median (IQR)) 
ILAR Active Joint Count Limited Joint Count ESR (mm/hr)  
 Baseline One-Year Baseline One-Year Baseline One-Year 
Whole Cohort 2 (1, 5) 0 (0, 1)* 1 (1, 3) 0 (0, 1)* 20 (6, 45) 9 (4, 20)* 
Systemic Arthritis 3 (1, 6) 0 (0, 1)* 0 (0, 4) 0 (0, 0)* 85 (55, 102) 25 (5, 43)* 
Persistent Oligoarthritis 1 (1, 2) 0 (0, 1)* 1 (1, 2) 0 (0, 1)* 13 (5, 30) 8 (5, 16)* 
Extended Oligoarthritis 3 (1, 6) 0 (0, 1)* 2 (1, 4) 1 (0, 1)* 34 (13, 53) 15 (9, 32) 
RF (-) Polyarthritis 8 (4, 14) 0 (0, 2)* 5 (2, 11) 1 (0, 3)* 28 (8, 56) 8 (4, 21)* 
RF (+) Polyarthritis 7 (5, 22) 1 (0, 5)* 2 (1, 16) 1 (0, 2) 18 (10, 46) 12 (6, 16)* 
ERA 2 (1, 5) 0 (0, 1)* 2 (1, 4) 0 (0, 2)* 16 (7, 32) 8 (3, 14)* 
PSA 3 (2, 5) 0 (0, 2)* 2 (1, 3) 1 (0, 2)* 26 (8, 43) 8 (3, 17)* 
Undifferentiated 1 (1, 6) 0 (0, 1)* 1 (1, 5) 0 (0, 2)* 14 (6, 35) 10 (5, 48) 
 Physician Global Score Parent General Evaluation Pain Score 
 Baseline One-Year Baseline One-Year Baseline One-Year 
Whole Cohort 31 (18, 56) 6 (1, 18)* 20 (5, 46) 6 (1, 27)* 32 (9, 57) 9 (1, 32)* 
Systemic Arthritis 57 (35, 72) 14 (3, 31)* 33 (7, 53) 9 (3, 36)* 42 (10, 50) 19 (7, 50) 
Persistent Oligoarthritis 24 (15, 43) 2 (0, 17)* 15 (3, 39) 4 (0, 21)* 24 (7, 50) 6 (0, 30)* 
Extended Oligoarthritis 36 (20, 61) 8 (4, 21)* 27 (7, 48) 9 (2, 36) 36 (7, 50) 14 (1, 30) 
RF (-) Polyarthritis 47 (30, 67) 9 (2, 18)* 32 (8, 53) 7 (2, 26)* 39 (12, 70) 8 (2, 25)* 
RF (+) Polyarthritis 39 (22, 67) 9 (4, 27)* 19 (15, 32) 42 (36, 70) 61 (21, 65) 41 (20, 59)* 
ERA 31 (21, 55) 8 (0, 15)* 22 (12, 50) 5 (0, 35)* 49 (21, 64) 8 (0, 51) 
PSA 30 (17, 45) 6 (1, 18)* 18 (3, 33) 8 (3, 24) 26 (9, 55) 9 (2, 32)* 
Undifferentiated 22 (11, 43) 8 (1, 24)* 16 (2, 28) 8 (1, 34) 21 (1, 66) 10 (1, 26)* 
* Improvement at one-year statistically significant at p<0.05 
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Table 3 Disability (measured using CHAQ score) at first presentation and an one-year in children with JIA 
 CHAQ at First Presentation CHAQ at One-Year 
JIA ILAR Subtype Median (IQR) % with CHAQ ≥0.75 Median (IQR) 
% with CHAQ 
≥0.75 
Whole Cohort 0.63 (0.13, 1.38) 50 0.25 (0, 1.0)* 32 
Systemic Arthritis 0.94 (0.25, 2.0) 54 0.5 (0.06, 1.5) 47 
Persistent Oligoarthritis 0.63 (0.13, 1.13) 46 0.13 (0, 0.75)* 27 
Extended Oligoarthritis 0.56 (0.38, 1.5) 45 0.56 (0.06, 1.19) 42 
RF (-) Polyarthritis 1.25 (0.38, 1.88) 65 0.38 (0.13, 1.5)* 40 
RF (+) Polyarthritis 1.13 (0.5, 1.5) 64 0.56 (0.13, 1.13)* 40 
ERA 0.5 (0.06, 1.19) 44 0.13 (0, 0.5)* 24 
PSA 0.38 (0.13, 1.0) 40 0.13 (0, 1.0) 30 
Undifferentiated 0.38 (0, 1.13) 36 0.19 (0, 1.19) 35 
*Improvement at one-year statistically significant at p<0.05
  14
Table 4 Details of Anti-Rheumatic Therapies Received In First Year Following Presentation, n (%) 
ILAR NSAID Systemic steroids* 
Intra-articular 
steroids 
Methotrexate  Biologics 
Whole Cohort 632 (85) 197 (27) 515 (70) 350 (47) 55 (7) 
Systemic Arthritis 35 (83) 37 (88) 11 (26) 33 (79) 7 (17) 
Persistent Oligoarthritis 300 (85) 41 (12) 261 (74) 65 (18) 3 (1) 
Extended Oligoarthritis 29 (91) 8 (25) 28 (88) 24 (75) 3 (9) 
RF (-) Polyarthritis 128 (86) 73 (49) 107 (72) 135 (91) 23 (16) 
RF (+)(Polyarthritis 20 (87) 12 (52) 10 (43) 21 (91) 5 (22) 
ERA 45 (88) 13 (25) 32 (63) 22 (43) 7 (14) 
PSA 50 (82) 8 (13) 44 (72) 38 (62) 5 (8) 
Undifferentiated 25 (83) 5 (17) 22 (73) 12 (40) 2 (7) 
*Included either oral or systemic steroids 
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Table 5 Predictors of CHAQ Score ≥0.75 at Presentation and at One-Year 
 Factors Associated with CHAQ ≥0.75 at First Presentation  Factors Associated with CHAQ ≥0.75 at One-Year  
Measure at First 
Presentation 
Univariate 
Analysis 
OR (95% CI) 
Multivariate 
Analysis 
OR (95% CI) 
Multivariate Analysis 
OR (95% CI) 
(Imputed Data) 
Univariate Analysis 
OR (95% CI) 
Multivariate Analysis 
OR (95% CI) 
Multivariate Analysis 
OR (95% CI) 
(Imputed Data) 
Age at Presentation 
 (per year) 
0.98 
(0.94, 1.02) 
0.92 
(0.86, 0.99) 
0.92 
(0.87, 0.98) 
0.99 
(0.95, 1.04) 
1.02 
(0.94, 1.10) 
1.00 
(0.95, 1.05) 
Male 1.00 
(0.69, 1.45) 
1.29 
(0.67, 2.47) 
1.03 
(0.64, 1.63) 
0.74 
(0.5, 1.09) 
0.59 
(0.30, 1.18) 
0.62 
(0.37, 1.03) 
Delay to Presentation (per 
month) 
1.00 
(0.99, 1.01) 
1.00 
(0.98, 1.02) 
0.99 
(0.98, 1.01) 
1.01 
(0.99, 1.02) 
1.00 
(0.99, 1.02) 
1.01 
(0.99, 1.02) 
Active Joint Count (per joint) 1.08 
(1.04, 1.12) 
1.09 
(1.03, 1.14) 
1.08 
(1.04, 1.12) 
1.03 
(1.01, 1.05) 
1.02 
(0.98, 1.05) 
1.00 
(0.97, 1.02) 
CHAQ ≥0.75 
   
5.61 
(3.41, 9.23) 
4.81 
(2.09, 11.07) 
3.92 
(2.17, 7.09) 
ESR (per 10mm/hr) 1.18 
(1.09, 1.27) 
1.14 
(1.02, 1.27) 
1.09 
(0.99, 1.21) 
1.08 
(1.01,1.16) 
1.03 
(0.93, 1.14) 
1.01 
(0.93, 1.10) 
Physician Global Assessment 
(per 10 mm) 
1.17 
(1.08, 1.27) 
0.98 
(0.85, 1.12) 
0.97 
(0.87, 1.09) 
1.16  
(1.06,1.26) 
0.93 
(0.80, 1.08) 
1.06 
(0.95, 1.18) 
Parent General Evaluation 
(per 10 mm) 
1.73 
(1.55, 1.93) 
1.46 
(1.24, 1.72) 
1.38 
(1.21, 1.56) 
1.32 
(1.21, 1.45) 
1.14 
(0.97,1.34) 
1.16 
(1.01, 1.32) 
Pain Score (per 10 mm) 1.60 
(1.46, 1.74) 
1.40 
(1.22, 1.60) 
1.40 
(1.25, 1.56) 
1.25 
(1.15, 1.35) 
1.01 
(0.86,1.17) 
1.00 
(0.90, 1.12) 
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